Pregabalin Capsule
Product Images NDC 71335-1555

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1555). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351555)

Label for PREGABALIN Capsules, USP 200 mg by Bryant Ranch Prepack. The label shows the NDC 71335-1555-01, with a package size of 30 capsules. Storage instructions and a barcode are also present, along with the BRP Pharmaceuticals logo.*

FDA Label Image

Label (Lbl7133515552)

Label for Pregabalin 200 mg capsules by Bryant Ranch Prepack. The label indicates it is an orange capsule, compares to Lyrica 200 mg capsules by Laurus Labs Limited, and contains 30 capsules. Storage instructions specify room temperature (20°-25°C). The label includes lot number 1523487, a barcode, and the NDC 71335-1555-51.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of pregabalin depicting its molecular configuration with isobutyl side chain, amino group, and carboxylic acid functional groups.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and an adjustment factor for female patients, shown as a text equation.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing varying degrees of pain improvement among these groups.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline. It features two lines representing Pregabalin 100 mg three times a day and placebo, showing a higher percent of patient improvement for the Pregabalin group. The x-axis shows percent improvement in pain, and the y-axis shows percent of patients improved.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved against percent improvement in pain from baseline. The graph compares Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day with a placebo. The vertical axis represents the percent of patients improved, and the horizontal axis displays the percent improvement in pain from baseline ranging from greater than 0 to 100.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line chart showing percent of patients improved plotted against percent improvement in pain from baseline. The chart compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, illustrating the relative effectiveness across different improvement thresholds.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient response rates relative to pain improvement percentages.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

Bar chart showing responder rates (%) for different dosages of pregabalin versus placebo in two clinical studies labeled Study E1 and Study E3. The x-axis lists placebo and pregabalin doses ranging from 50 mg/day to 600 mg/day, while the y-axis shows responder rates from 0% to 60%. Data indicate increasing responder rates with higher pregabalin doses compared to placebo.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph showing seizure reduction (median % change from baseline) plotted against dose in mg/day. The graph compares data from four studies (E1 BD, E2 TID, E3 BD, E3 TID) indicated with different markers. The chart includes statistically significant p-values associated with the data points, showing seizure reduction increases with higher doses, up to 600 mg/day.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph showing the percentage of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The graph compares Pregabalin doses of 600 mg, 450 mg, and 300 mg daily to placebo, illustrating patient improvement trends across these groups.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A line graph displaying the estimated percentage of subjects without LTR over a period of 180 days. Two lines represent Pregabalin and Placebo treatment groups, showing higher percentages of subjects without LTR in the Pregabalin group compared to the Placebo group throughout the timeframe.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph showing the percent of subjects improved over increasing percent improvement from baseline to week 12, comparing Pregabalin and Placebo. The graph plots percent improved on the y-axis against percent improvement from baseline on the x-axis, with two curves representing Pregabalin and Placebo response rates.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percent of subjects improved from baseline to week 16 between Pregabalin and placebo groups. The x-axis represents the percent improvement ranging from greater than 0 to 100, while the y-axis shows the percent of subjects improved up to 90%. A solid line represents Pregabalin, and a dashed line represents placebo, illustrating higher improvement rates with Pregabalin across the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.